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Figure 2. Bozniak classification of renal cysts: Type 1 refers to a unilocular thin-walled 
cyst with no enhancement. A type 2 cyst contains thin non-enhancing septa and may 
show thin calcifications. Hyperdense (haemorrhagic) cysts measuring <3cm in diameter 
are also considered type 2 lesions. Hyperdense cysts ≥3cm and those with minimal septal 
nodularity and minimal enhancement are considered type 2F (F indicates need for follow-
up). Cysts with thick nodular enhancing septa (Type 3) and those with solid enhancing 
proliferations (Type 4) are considered malignant and require management.
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renal cell cancer (RCC) is common, and its incidence is increasing due to increasing exposure to risk factors which include tobacco use, hypertension and obesity. Localised renal cancers are often 
detected incidentally, and their increased incidence also results from 
the increased use of imaging. Localised renal cancer now accounts 
for 60-70% of new RCC cases. Many of these cancers are slow 
growing and show little tendency to metastasize. 
Only a minority of patients with localised renal cell cancer 
have any clinical signs such as haematuria or abdominal pain. 
These tumours are often detected incidentally on ultrasound 
but are best characterised using computed tomography (CT), 
where they may appear as a solid contrast-enhancing mass or a 
complex cystic lesion. Imaging features are similar on Magnetic 
Resonance Imaging (MRI) and the latter is equally accurate for 
the evaluation of renal lesions; it may be used in patients who 
are allergic to iodinated contrast material, in those with poor 
renal function, in lesions containing complex haemorrhage or 
where radiation exposure must be avoided (e.g. pregnancy). 
Localised renal cancer is defined as a stage I or II tumor that 
remains confined within the renal capsule (Fig 1). Since renal 
cancers may be cystic, it is important to identify those features 
in cystic lesions which point towards malignant disease. In 1986, 
Morton Bozniak suggested a classification of cystic lesions based 
on CT findings to help standardise their management (Fig 2). This 
cyst classification system has since then become widely accepted 
and is used to guide treatment decisions. Bosniak Type III and IV 
lesions are very likely malignant and require further management. 
Management options for localised renal cancer include 
radical nephrectomy, partial nephrectomy, thermal ablation and 
active observation. The choice of treatment is individualised 
based on patient age and co-morbidities, tumor characteristics 
and renal function considerations. A significant proportion of 
localised RCCs are indolent and slow growing; they can therefore 
be managed by nephron-sparing treatments (partial nephrectomy 
or thermal ablation) or even through active observation. The 
new American Urological Association (AUA) 2017 guidelines 
recommend a change in strategy with a decreased use of radical 
nephrectomy and an increased use of imaging-guided renal 
biopsy, thermal ablation and active observation. 
Radical nephrectomy is the preferred treatment in patients 
with aggressive tumor types, for larger tumours that show 
complex or infiltrative imaging features (Fig 3 and 4) and when 
normal contralateral renal function is present. 
Partial nephrectomy or tumour enucleation can be considered in 
tumours <4cm in diameter (Fig 5). These should also be considered 
in patients with an anatomical or functional solitary kidney, for 
bilateral or multifocal tumours, for patients with familial renal cell 
cancer, for young patients, and for those with limited renal function 
or with comorbidities that could lead to deterioration in renal 
function. In otherwise healthy individuals who present with a lesion 
that shows aggressive imaging features, a partial nephrectomy or 
enucleation is recommended without prior biopsy.
Imaging-guided tumour biopsy provides a means of 
confirming the diagnosis of malignancy and establishing the 
tumour subtype (and consequently the degree of aggressiveness 
of the tumour). In the past, it was claimed that percutaneous 
biopsy was associated with an increased risk of tumor seeding 
Figure 1. Renal cancer staging: Stage I and II lesions are considered local renal 
cancers as they do not extend beyond the renal capsule. Source: http://www.
aboutcancer.com/renal_cell_stage_survival_nejm.jpeg
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Figure 7. Two CT scans obtained one year apart in a 77-year old woman showing 
a right renal tumour that has increased in size from 12mm (arrow) to 14mm in 
diameter in the interval. Continuing with active observation is the ideal approach 
in these circumstances. 
that laparoscopic guidance and can be done under local anaesthesia. 
Imaging-guided core biopsy should always be performed prior to 
thermal ablation. Patients undergoing thermal ablation must be 
informed of an increased likelihood of persistence or recurrence of 
the tumour, which can be addressed by repeating the ablation.
In patients who are unfit for or unwilling to accept surgery and 
who have a non-aggressive appearing lesion, active observation 
with sequential imaging is advised. Active surveillance according 
to AUA guidelines should be used when anticipated risks of 
intervention or competing risks of death outweigh the potential 
benefits of active treatment. The said guidelines also state that 
active surveillance may be used as an initial management option in 
patients with suspicious lesions <2cm in diameter (Fig 7). However, 
the patient must clearly understand the risks of tumour growth and 
the importance of returning for a follow-up CT scan in 3-6 months. 
If lesion size increases to >3cm, if there is a growth rate of >5mm 
per year, or if there is an increase in tumour stage, a change in 
treatment strategy should be offered. 
In summary, the current tendency is to move away from radical 
nephrectomy to nephron-sparing procedures for Stage 1 and 2 
renal tumours. The increasing evidence that smaller tumours may 
be less aggressive or even indolent has changed recommended 
treatment protocols to favour more conservative surgery, thermal 
ablation or even active monitoring with imaging. 
Figure 6. CT scans showing a T1 tumor (arrows in A and B) in the lower pole of 
the right kidney. Image B shows a radiofrequency ablative probe place centrally 
within the lesion inserted under CT guidance. 
Figure 3. Contrast-enhanced CT scan showing a complex enhancing tumour 
(arrow) in the lower pole of the left kidney. No hilar, vascular or lymph node 
involvement is evident. 
Figure 4. CT Scan Bosniak type IV cystic lesion (arrow) showing thick 
enhancing walls. Minimal perinephric fat stranding is also present. 
Figure 5. CT scan showing a Stage 1 lesion consisting of a 3cm mass (arrows) in the 
lower pole of the left kidney that demonstrates heterogeneous enhancement with 
central necrosis; the tiny peripheral nodules adjacent to the renal capsule represent 
blood vessels and not tumour extension. The renal vein (arrowheads) is filled with 
contrast material confirming absence of intravascular extension of the tumour.
along the biopsy tract. However, this is now known to be 
exceedingly rare particularly when using a coaxial technique; 
this technique allows multiple samples to be obtained and 
thermal ablation to be performed through a single tract.
Thermal ablation can be a considered treatment option when 
nephron-sparing is a priority and in patients who are unfit for 
surgery. In patients who are frail, who suffer from multiple co-
morbidities or who refuse surgical intervention, and who have 
aggressive-looking lesions, biopsy and ablation may be performed 
in the same sitting. Tumour ablation is used for Stage 1 tumours and 
obtains most reliable results in tumours <3cm in diameter (Fig 6). 
Radiofrequency ablation or cryoablation may be implemented under 
imaging or laparoscopic guidance. Imaging guidance is more efficient 
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